Time from study entry to virologic failure at Weeks 24, 48 and 96 [clinicaltrials_resource:c689679f149bbe4ff7b19b5b94c025f3]

Time from study entry to virologic failure at Weeks 24, 48 and 96 [clinicaltrials_resource:c689679f149bbe4ff7b19b5b94c025f3]

Click here for more information about lopinavir/ritonavir
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:c689679f149bbe4ff7b19b5b94c025f3
Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients [clinicaltrials:NCT00050895]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Time from study entry to virologic failure at Weeks 24, 48 and 96 [clinicaltrials_resource:c689679f149bbe4ff7b19b5b94c025f3]

Click here for more information about lopinavir/ritonavir
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:c689679f149bbe4ff7b19b5b94c025f3
Bio2RDF identifier
c689679f149bbe4ff7b19b5b94c025f3
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c689679f149bbe4ff7b19b5b94c025f3
measure [clinicaltrials_vocabulary:measure]
Time from study entry to virologic failure
time frame [clinicaltrials_vocabulary:time-frame]
description
Click here for more information about lopinavir/ritonavir
identifier
clinicaltrials_resource:c689679f149bbe4ff7b19b5b94c025f3
title
Time from study entry to virologic failure at Weeks 24, 48 and 96
@en
inDataset
type
label
Time from study entry to virol ...... 9679f149bbe4ff7b19b5b94c025f3]
@en